Skip to main content
Log in

The Costs and Benefits of Switching a Drug from Prescription-Only to Over-the-Counter Status

A Review of Methodological Issues and Current Evidence

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

In recent years various governments, pharmacy associations, consumer groups and the pharmaceutical industry have suggested that more drugs should be switched from prescription-only (Rx) to over-the-counter (OTC) status. Many rationales have been offered, including lowering healthcare costs, taking advantage of pharmacists’ training and knowledge, promoting the concept of prevention and self-care, and increasing sales of pharmaceuticals.

The purpose of this article is to examine the current state of knowledge on assessing the effects of such a change. First, the paper discusses the methodology and data necessary for conducting an assessment of the costs and benefits of switching a drug from Rx to OTC status. Basically two methods, the economic theory of consumers’ surplus and the epidemiological approach, are available; the choice of method depends on the drug examined and the data available.

Secondly, the article discusses existing evidence pertaining to the costs and benefits of these switches. Based on our review of the literature, we conclude that the benefits, to individual consumers and to society as a whole, resulting from a change in prescription status outweigh the costs. The extent of the benefits depends on the type of drug and the size of the market.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Andersen M, Schou JS. Adverse reactions to histamine H2 receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status. Pharmacology and Toxicology 69: 253–258, 1991

    PubMed  CAS  Google Scholar 

  • Anon. H2 antagonists go OTC in Denmark. Pharmaceutical Journal 242: 308–309, 1989

  • Anon. Call for more POM to P in UK. Scrip 1679/1680: 6, 1991a

  • Anon. Little impact from NHS reforms? Scrip 1675: 5, 1991b

  • Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford, 1987

    Google Scholar 

  • Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Höög S. Self-medication in Sweden from an industry perspective. Paper presented at the First Workshop on Strategies for the European Pharmaceutical Industry and Patient Interests. Brussels, January 31 to February 1, Management Centre Europe. 1–12, 1991

  • Oster G, Juse D, Delea T, Colditz G, Richter J. The risks and benefits of an Rx-to-OTC Switch. Medical Care 28: 834–852, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ryan M, Yule B. The economics of switching drugs from prescription-only to over-the-counter availability. Health Economics Research Unit Discussion Paper 02/88, University of Aberdeen, Aberdeen, 1988

  • Ryan M, Yule B. Switching drugs from prescription-only to over-the-counter availability: economic benefits in the United Kingdom. Health Policy 16: 233–239, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ryan M, Yule B. Benefits from switching drugs from prescription-only to over-the-counter availability: the UK experience. Paper presented at the First Workshop on Strategies for the European Pharmaceutical Industry and Patient Interests. Brussels. January 31 to February 1, Management Centre Europe, 1–15, 1991

    Google Scholar 

  • Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. New England Journal of Medicine 316: 450–455, 1987

    Article  PubMed  CAS  Google Scholar 

  • Smith DG, Kirking DM. Impact of consumer fees on drug utilisation. PharmacoEconomics 2: 335–342, 1992

    Article  PubMed  CAS  Google Scholar 

  • Temin P. Costs and benefits of switching drugs from Rx to OTC. Journal of Health Economics 2: 187–205, 1983

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andersson, F., Hatziandreu, E. The Costs and Benefits of Switching a Drug from Prescription-Only to Over-the-Counter Status. PharmacoEconomics 2, 388–396 (1992). https://doi.org/10.2165/00019053-199202050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199202050-00006

Keywords

Navigation